Unicycive Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
UNCY$3.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2022 and 2023
Balance Sheets
(in thousands, except for share and per share amounts)
| As of | As of | |
|---|---|---|
| December 31, | December 31, | |
| 2022 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash | $455 | $9,701 |
| Prepaid expenses and other current assets | 2,189 | 3,698 |
| Total current assets | 2,644 | 13,399 |
| Right of use asset, net | 152 | 766 |
| Property, plant and equipment, net | 22 | 26 |
| Total assets | $2,818 | $14,191 |
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $892 | $839 |
| Accrued liabilities | 2,237 | 3,234 |
| Warrant liability | - | 13,134 |
| Operating lease liability – current | 155 | 327 |
| Total current liabilities | 3,284 | 17,534 |
| Operating lease liability – long term | - | 466 |
| Total liabilities | 3,284 | 18,000 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ deficit: | ||
| Series A-2 preferred stock, $0.001 par value per share – zero and 43,649 shares authorized at December 31, 2022 and December 31, 2023, respectively; zero and 43,649 shares outstanding at December 31, 2022 and December 31, 2023, respectively | - | - |
| Preferred stock: $0.001 par value per share—10,000,000 and 9,926,161 shares authorized at December 31, 2022 and December 31, 2023, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2023 | - | - |
| Common stock, $0.001 par value per share – 200,000,000 shares authorized at December 31, 2022 and December 31, 2023; 15,231,655 shares issued and outstanding at December 31, 2022 and 34,756,049 issued and outstanding at December 31, 2023 | 15 | 35 |
| Additional paid-in capital | 33,516 | 60,697 |
| Accumulated deficit | (33,997) | (64,541) |
| Total stockholders’ deficit | (466) | (3,809) |
| Total liabilities and stockholders’ deficit | $2,818 | $14,191 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.